V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160013648 | 160006647 | 1.79 | 97.7 | Adjuvant (A) | 2019-03-06 | 2019-03-13 | STS Rhabdomyosarcoma RMS 2005 IVADo | null | N | NOT MATCHED | 100086219 |
| 160013649 | 160006648 | 1.48 | 86.7 | null | 2019-10-13 | 2019-10-19 | DOXORUBICIN | 2 | N | DOXORUBICIN + IFOSFAMIDE | 100001401 |
| 160013651 | 160006649 | 1.62 | 73 | Palliative (P) | 2012-11-23 | 2012-12-01 | Doxorubicin 75mg/m2 | 02 | N | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 101226711 |
| 160013652 | 160006650 | 1.59 | 80 | Palliative (P) | 2019-04-07 | 2019-04-09 | IPM | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100121746 |
| 160013653 | 160006651 | 1.79 | 65 | null | 2018-10-03 | 2018-10-07 | ETOP 13-18 BEAT-meso Trial | 02 | null | ETOP 13-18 BEAT-MESO TRIAL | 101048235 |
| 160013655 | 160006652 | 1.8 | 70.9 | 03 | 2018-05-17 | 2018-05-23 | Doxorubicin 75mg/m2 | null | N | DOXORUBICIN | 101307641 |
| 160013656 | 160006653 | 1.62 | 91 | Neo-adjuvant (N) | 2018-01-05 | 2018-01-05 | BEVACIZUMAB + CARBO + PACLITAXEL | 02 | N | STS RHABDOMYOSARCO RMS 2005 IVADOVV | 100504616 |
| 160013657 | 160006654 | 1.65 | 47.3 | Palliative (P) | 2019-03-19 | 2019-04-06 | STS Rhabdo RMS 2005 | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100402323 |
| 160013658 | 160006655 | 1.58 | 45.8 | Palliative (P) | 2018-06-01 | 2018-06-02 | Trial Unspecified | 02 | N | LIPOSOMAL DOXORUBICIN | 101036380 |
| 160013660 | 160006656 | 1.65 | 75 | Palliative (P) | 2019-08-05 | 2019-08-06 | Obinutuzumab +CHOP | null | N | DOXORUBICIN + OLARATUMAB | 100601404 |
| 160013664 | 160006657 | 1.74 | 100.2 | Palliative (P) | null | 2019-12-23 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101764658 |
| 160013666 | 160006658 | 1.82 | 70 | Adjuvant (A) | null | null | Trial Unspecified | 01 | Y | STS RHABDOMYOSARCO RMS 2005 IVADOVV | 101750850 |
| 160013668 | 160006659 | 1.69 | 82 | null | 2016-04-25 | 2016-05-14 | Liposomal Doxorubicin (Caelyx) | N | N | EPIRUBICIN | 100456317 |
| 160013671 | 160006660 | 1.76 | 75.5 | Palliative (P) | 2016-12-15 | 2016-12-26 | BEVACIZUMAB + CARBO + PACLITAXEL | 01 | N | DOXORUBICIN | 101509981 |
| 160013672 | 160006661 | 1.59 | 78 | Palliative (P) | null | null | EW EuroEwing 2012 Arm B VDC | 02 | null | IMATINIB | 100643034 |
| 160013673 | 160006662 | 1.54 | 90.4 | Palliative (P) | 2017-03-03 | 2017-04-14 | Liposomal Doxorubicin (Caelyx) | 02 | N | CARBOPLATIN + PACLITAXEL | 101643409 |
| 160013677 | 160006664 | 1.73 | 71 | Palliative (P) | 2018-04-17 | 2018-04-18 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101119609 |
| 160013680 | 160006665 | 0 | 0 | Palliative (P) | 2016-09-04 | 2016-10-01 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101532953 |
| 160013681 | 160006666 | 1.86 | 59.65 | Palliative (P) | 2020-01-14 | 2020-02-02 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100312028 |
| 160013685 | 160006667 | 1.71 | 77.9 | Palliative (P) | 2020-08-03 | 2020-08-03 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101260401 |
| 160013686 | 160006668 | null | null | Palliative (P) | 2022-01-12 | 2022-01-12 | Dasatinib | 02 | null | CARBOPLATIN + PACLITAXEL | 100662996 |
| 160013687 | 160006669 | 1.6 | 78 | Palliative (P) | 2016-12-23 | 2017-01-06 | Paclitaxel 80mg/m2 day 1 8 15 | 2 | N | DOXORUBICIN + IFOSFAMIDE | 101628299 |
| 160013691 | 160006670 | 1.66 | 128 | Neo-adjuvant (N) | null | 2017-03-06 | Cisplatin + Pemetrexed | 01 | null | CISPLATIN + PEMETREXED | 101719910 |
| 160013693 | 160006671 | null | 108 | Neo-adjuvant (N) | 2017-11-14 | 2017-11-26 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101675459 |
| 160013694 | 160006672 | 1.56 | 83 | null | 2017-12-24 | 2017-12-28 | Cisplatin + Pemetrexed | 01 | null | CISPLATIN + PEMETREXED | 100456431 |
| 160013695 | 160006673 | 1.83 | 75.8 | Palliative (P) | 2018-03-07 | 2018-03-15 | Cisplatin + Pemetrexed | 2 | N | CISPLATIN + PEMETREXED | 100921909 |
| 160013697 | 160006674 | 1.65 | 59 | null | 2021-08-10 | 2021-09-11 | Carboplatin + Etoposide iv&po | 01 | N | CARBOPLATIN | 100151224 |
| 160013698 | 160006675 | 1.74 | 48.2 | Neo-adjuvant (N) | 2016-02-24 | 2016-02-24 | Dactinomycin + Vincristine | 01 | N | DOXORUBICIN + IFOSFAMIDE | 100148508 |
| 160013699 | 160006676 | 1.58 | 60.2 | Palliative (P) | 2017-07-26 | 2017-08-10 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 100641508 |
| 160013701 | 160006677 | 1.72 | 62.3 | null | 2017-04-02 | 2017-04-03 | ETOP 13-18 BEAT-meso Trial | 02 | N | EPSSG | 101405344 |
| 160013703 | 160006678 | 1.78 | 58.1 | Palliative (P) | 2019-02-19 | 2019-03-02 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101410823 |
| 160013704 | 160006679 | 1.81 | 0 | Palliative (P) | 2018-05-01 | 2018-05-16 | Pemetrexed | N | Y | DOXORUBICIN + IFOSFAMIDE | 100982442 |
| 160013705 | 160006680 | 1.74 | 68.4 | Palliative (P) | 2018-01-24 | 2018-01-24 | Cisplatin + Pemetrexed | 2 | N | CISPLATIN + PEMETREXED | 101832521 |
| 160013706 | 160006681 | 1.66 | 113.1 | Palliative (P) | 2019-09-16 | 2019-09-20 | Cisplatin + Pemetrexed | 02 | Y | CISPLATIN + PEMETREXED | 101004240 |
| 160013711 | 160006682 | 1.46 | 72 | Curative (C) | 2018-11-02 | 2018-11-02 | Liposomal Doxorubicin 40mg/m2 | 02 | N | DOXORUBICIN | 101106515 |
| 160013713 | 160006683 | null | null | Palliative (P) | 2016-05-11 | 2016-05-26 | WT SIOP 2002 01 post op Carbo, Etop | 02 | null | PEMETREXED | 100414314 |
| 160013715 | 160006684 | 1.75 | 83.2 | Palliative (P) | null | 2019-06-06 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 02 | N | TRIAL | 100058140 |
| 160013718 | 160006685 | 1.68 | 115 | Palliative (P) | 2016-09-09 | 2016-09-21 | STS Non-Rhabdo EpSSG 2005 Ifos Dox | 02 | N | EW EUROEWING 2012 ARM B VDC | 100599617 |
| 160013723 | 160006686 | 1.93 | 95.7 | Palliative (P) | 2020-02-23 | 2020-03-01 | EURO-EWING | 02 | Y | NB HRNBL-1 COJEC IND COURSE A | 100549068 |
| 160013725 | 160006687 | 1.73 | 75 | Palliative (P) | 2016-04-12 | 2016-04-22 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101380214 |
| 160013727 | 160006688 | 1.55 | 72 | null | null | 2019-02-20 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100746677 |
| 160013728 | 160006689 | 1.59 | 53.2 | Palliative (P) | 2018-05-25 | 2018-05-26 | Carboplatin AUC 2 - 5 | 02 | N | CARBOPLATIN | 101165246 |
| 160013730 | 160006690 | 0 | 12.8 | Curative (C) | 2018-02-16 | 2018-02-18 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 100661362 |
| 160013734 | 160006691 | 1.51 | 17.4 | Palliative (P) | null | 2017-03-28 | CISPLATIN + ETOPOSIDE | n | N | TRIAL UNSPECIFIED | 100790731 |
| 160013735 | 160006692 | 1.71 | 78 | Palliative (P) | 2020-10-17 | 2020-10-19 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 100387491 |
| 160013737 | 160006693 | 1.73 | 105 | Adjuvant (A) | 2018-10-26 | 2018-11-07 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 100389343 |
| 160013738 | 160006694 | 1.62 | 70.4 | Palliative (P) | 2016-05-23 | 2016-06-20 | Doxorubicin + Olaratumab | Y | null | TRIAL UNSPECIFIED | 100509423 |
| 160013740 | 160006695 | 1.74 | 72 | Palliative (P) | 2019-11-25 | 2019-11-26 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100516327 |
| 160013741 | 160006696 | 1.65 | 66 | Palliative (P) | null | 2017-12-28 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100031118 |
| 160013742 | 160006697 | 1.65 | 85.9 | Palliative (P) | 2017-12-07 | 2017-12-07 | Doxorubicin + Olaratumab | 02 | N | STS RHABDOMYOSARCO RMS 2005 IVADOVV | 100743894 |